Fosun Pharma plans HKD 1 billion buyback. Fosun Pharma stock sits 31.29 percent below its high

Published on 10/07/2026 at 01:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 4.75 percent to CNY 20.44 billion. Fosun Pharma stock stood at EUR 2.07 on October 5, 2026 after EUR 2.07.

Fosun Pharma, CNE100001M79, Illustration mit AI erstellt.

Fosun Pharma stock (ISIN CNE100001M79) had a Lang & Schwarz prior close of EUR 2.07 for October 5, 2026. The company announced a proposed HKD 1.00 billion H-share repurchase plan on September 6, 2026, according to The Standard citing Reuters. For investors, the buyback puts capital allocation alongside the company's growth program.

Buyback targets H shares

The proposed mandate covers up to HKD 1.00 billion of repurchases. The board said market conditions could determine whether repurchased shares are canceled or held as treasury shares, while the plan remains subject to the company's mandate and applicable requirements, The Standard reported on September 6, 2026.

The same report said Fosun Pharma Singapore sold 9,897,000 Gland Pharma shares for INR 28.00 billion, equivalent to HKD 2.32 billion before costs. That transaction gives the repurchase plan a wider capital-allocation context, because the company is simultaneously monetizing part of an international healthcare holding.

First-half revenue gains ground

Fosun Pharma recorded CNY 20.44 billion of revenue in the first half of 2026, up 4.75 percent year over year, according to Seeking Alpha in its transcript of the September 22, 2026 results briefing. Innovative-drug revenue reached CNY 4.91 billion, an increase of 13.84 percent from the year-earlier period.

International operations added another growth signal. Overseas revenue increased 16.45 percent in the first half of 2026, while research and development expenditure reached CNY 3.25 billion, up 25.66 percent year over year, according to Seeking Alpha. The combination of innovative-drug growth and higher research spending shows where management is directing operating resources.

H shares remain below yearly high

At the HKEX listing, the October 6, 2026 quote was HKD 18.29, compared with a 52-week high of HKD 26.62. The gap was 31.29 percent, calculated against the high, while market capitalization stood at HKD 68.5 billion and trading volume at 838,000 shares on the same date.

Fosun Pharma operates across pharmaceutical manufacturing, medical devices, diagnostics and healthcare services. Its first-half revenue growth was slower than the 13.84 percent expansion of innovative-drug revenue, making product mix and international execution important indicators for the next reported period.

Capital allocation meets innovation

Fosun Pharma combines a proposed HKD 1.00 billion repurchase with CNY 3.25 billion of first-half research spending. The contrast defines the investor debate: capital returns can support the H-share valuation, while the higher innovation budget must translate into durable product growth.

Lang & Schwarz showed the prior close at EUR 2.07 for October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Fosun Pharma stock.